Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01301716 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT01301716 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 75 participants.
The verdict
NCT01301716, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid tumors.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG bevacizumab
- DRUG paclitaxel
- DRUG GDC-0980
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01301716
The ClinicalTrials.gov registry entry for NCT01301716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT01301716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01301716 about?
NCT01301716 is a clinical study titled "A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors". This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid ...
What is the current status of trial NCT01301716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2011-09. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01301716?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), bevacizumab (DRUG), paclitaxel (DRUG), GDC-0980 (DRUG).
Who is sponsoring clinical trial NCT01301716?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.